Revolutionary Sepsis Test: Saving Lives and Costs in Emergency Departments

Independent research led by Pennsylvania State University has found that Cytovale's IntelliSep sepsis test is both cost-effective and slightly more accurate than procalcitonin testing, a widely available biomarker diagnostic for sepsis. The study predicts that over 95% of sepsis patients could survive at a cost of less than $4000 per patient using the IntelliSep test. Accurate and timely diagnosis of sepsis is crucial for successful treatment, and the IntelliSep test, which analyzes white blood cell shape and structure, could help save lives and reduce healthcare costs.